Background. Bartter syndrome (BS) is clinically classified into antenatal or neonatal BS (aBS) and classic BS (cBS) as well as five subtypes based on the underlying mutant gene; SLC12A1 (BS I), KCNJ1 (BS II), CLCNKB (BS III), BSND (BS IV) and CASR (BS V). Methods. Clinico-genetic features of a nationwide cohort of 26 Korean children with BS were investigated. Results. The clinical diagnosis was aBS in 8 (30.8%), cBS in 15 (57.7%) and mixed Bartter-Gitelman phenotype in 3 cases (11.5%). Five of eight patients with aBS and all 18 patients with either cBS or mixed Bartter-Gitelman phenotype had CLCNKB mutations. Among the 23 patients (46 alleles) with CLCNKB mutations, p.W610X and large deletions were detected in 25 (54.3%) and 10 (21.7%) alleles, respectively. There was no genotype-phenotype correlation in patients with CLCNKB mutations. Conclusions. Twenty-three (88.5%) of the 26 BS patients involved in this study had CLCNKB mutations. The p.W610X mutation and large deletion were two common types of mutations in CLCNKB. The clinical manifestations of BS III were heterogeneous without a genotype-phenotype correlation, typically manifesting cBS phenotype but also aBS or mixed Bartter-Gitelman phenotypes. The molecular diagnostic steps for patients with BS in our population should be designed taking these peculiar genotype distributions into consideration, and a new more clinically relevant classification including BS and Gitelman syndrome is required.
Introduction
Bartter syndrome (BS) is caused by defective salt reabsorption in the thick ascending limb of the loop of Henle and is characterized by renal salt wasting, hypokalemia, metabolic alkalosis, hypereninemic hyperaldosteronism with normal blood pressure and hyperplasia of the juxtaglomerular apparatus [1] . BS is a heterogeneous disorder, both clinically and genetically, that can be classified into two clinical variants, aBS and cBS according to the onset age. In addition, BS can also be classified into at least five genetic subtypes according to the underlying mutant gene, all of which are expressed in the tubular epithelial cells of the thick ascending limb of the loop of Henle. Specifically, BS type I (BS I) is caused by loss-of-function mutations in the SLC12A1 gene encoding the apical sodium-potassium-chloride co-transporter, NKCC2. BS II is caused by loss-of-function mutations in the KCNJ1 gene encoding the apical inwardly rectifying potassium channel, ROMK. BS III is caused by loss-of-function mutations in the CLCNKB gene encoding the basolateral chloride channel, ClC-Kb. BS IV is characterized by loss-of-function mutations in the BSND gene encoding barttin, a b-subunit for ClC-Ka and ClC-Kb. Finally, BS V is characterized by gain-of-function mutations in the CASR gene encoding the basolateral calcium-sensing receptor, CaSR [2] [3] [4] [5] [6] . Some experts [7] classify loss-offunction mutations in alleles of both CLCNKA (encoding ClC-Ka) and CLCNKB as BS V, which results in a phenotype indistinguishable from that of BS IV [8, 9] . Gitelman syndrome (GS), another clinical variant of Bartter-like syndrome, is caused by loss-of-function mutations in the SLC12A3 gene encoding the apical sodium chloride cotransporter, NCCT, located in the distal convoluted tubule [10] . Although GS presents with hypokalemia and metabolic alkalosis similar to BS, it can be distinguished from BS with a less severe manifestation, delayed presentation in late childhood or adulthood, low urinary calcium excretion and hypomagnesemia [11] .
BS I-IV are autosomal recessive disorders, whereas BS V is an autosomal dominant disorder. Patients with BS I or II usually present as aBS [2, 3] , while some patients with BS II only present with transient hyperkalemia in the first week of life [12] . BS III usually manifests as cBS [4] ; however, some patients present as aBS GS, or a mixed Bartter-Gitelman phenotype [11, 13] . BS IV is specifically accompanied by sensorineural deafness and some of these patients develop chronic renal failure at a young age [5] . BS V is characterized by hypocalcemia due to hypoparathyroidism [6] .
In this study, we conducted an analysis investigating the genetic mutation basis of BS patients in Korea.
Materials and methods

Patients
A total of 26 unrelated Korean patients with BS were included in this nationwide multi-center study, organized by the Korean Society of Pediatric Nephrology. None of the participants were an offspring of consanguineous parents. Informed consent was obtained from either the patient or the parents of the patient. The Institutional Review Board of Seoul National University Hospital, Seoul, Korea gave an approval of the protocols used in this study.
Phenotype analysis
Clinical and laboratory findings of the patients were retrospectively analyzed by reviewing their medical records. In this study, patients were classified as aBS if they had antenatal (a history of polyhydrmanios or low birth weight) or neonatal (within the first month of life) onset, and patients were classified as cBS if their disease manifested beginning at the second month of life or later, without perinatal problems. Patients were defined as having a mixed Bartter-Gitelman phenotype if they presented with hypomagnesemia without hypercalciuria/nephrocalcinosis. The presence of nephrolcalcinosis was identified by renal ultrasonography. Chronic renal failure was defined as an estimated glomerular filtration rate with the Schwartz formula of 60 mL/min/1.73m 2 [14] .
Genotype analysis
Total DNA was extracted and purified from peripheral leukocytes of all patients and their available family members by standard phenol-chloroform extraction methods. All coding exons with flanking introns of the five genes (SLC12A1, KCNJ1, CLCNKB, BSND and CASR) were amplified using polymerase chain reaction (PCR) and direct sequencing (primer sequences are available upon request). If a patient was confirmed to have a pathogenic mutation in any one of the five genes, no further genetic analyses were done. Molecular analysis was done on the parents of 20 patients, and results of the analyses showed that none of the patients had a de novo mutation. In patients with an electropherogram that demonstrated a single mutant peak showing c.G1830A (p.W610X) mutation in the CLCNKB gene, homozygocity or heterozygocity of the mutation was confirmed by a multiplex ligation-dependent probe amplification (MLPA) method for detecting large heterozygous deletion and/or DNA sequencing of the parents' samples. If both parents were heterozygous for the c.G1830A mutation, the patient was diagnosed to be homozygous for the mutation. Otherwise, MLPA assay was performed in the other cases. Six novel missense mutations, which were detected in this study (p.L560P in SLC12A1, p.G47E in KCNJ1 and p.G120V, p.P216L, p.G424R and p.G437R in CLCNKB), were not detected in 100 Korean subjects in the control group, and the translated amino acids from these novel missense mutations were conserved in many different species.
Detection of large deletions of in the CLCNKB gene MLPA was conducted to identify heterozygous gross deletions in the CLCNKB gene using a commercial kit (Salsa MLPA Kit P266-A1 CLCNKB; MRC-Holland B. V., Amsterdam, The Netherlands). The amplified fragments were separated by capillary electrophoresis (a 36 cm capillary ABI 3130 Genetic Analyzer; Applied Biosystems, Foster City, CA). To detect the breakpoint of the large heterozygous deletion within the neighboring genes CLCNKA and CLCNKB, PCR analysis was done using a pair of PCR primers, which were described in previous studies by others [9, 15] . The exon numbering of CLCNKB and CLCNKA were based on reference messenger RNA sequences, GenBank accession number NM_000085.3 and NM_001042704.1, respectively.
Results
Eight patients (30.8%) presented as aBS, 15 patients (57.7%) presented as cBS and 3 patients (11.5%) presented with mixed Bartter-Gitelman phenotype. Three of these patients had one or more affected siblings. A history of polyhydramnios was present in seven of eight patients with aBS, but none of the patients with cBS had such a history. Among the eight patients with aBS, four patients were born prematurely (gestational ages 24-35 weeks) but with an adequate weight for gestational age (birth weight 0.83-2.90 kg), while the remaining four patients were full-term with a history of polyhydramnios and two of those patients were small for their gestational age.
Of the eight patients with aBS, one had SLC12A1 mutation (BS I), another had KCNJ1 mutation (BS II), a third had BSND mutation (BS IV) and the remaining five patients had CLCNKB mutation (BS III). The clinical and genetic features of the three patients with non-BS III are summarized in Table 1 . A detailed case report of the patient with BS IV has previously been reported [16] . All 18 patients with either cBS or mixed Bartter-Gitelman phenotype had CLCNKB mutation (BS III). The laboratory findings of the total 23 patients with BS III were compared according to their clinical features in Table 2 . There was no difference in the prevalence of hypercalciuria, nephrocalcinosis and hypomagnesemia between patients with aBS and cBS, but there was no prevalence of these symptoms in patients with mixed Bartter-Gitelman phenotype. All patients who developed nephrocalcinosis had hypercalciuria. Serum electrolyte and acid-base status of the patients were hard to compare among three subgroups due to the small number of patients in each groups and wide range of variations between their lab results.
Among the 23 patients (46 alleles) with CLCNKB mutations, a nonsense mutation of p.W610X was detected in 25 alleles (54.3%), a large deletion in 10 alleles (21.7%), a missense mutation in 7 alleles (15.2%) and a frame-shifting short insertion or deletion mutation in 4 alleles (8.7%). Among 10 large deletions, 8 were total and 2 were partial deletion. Two partial deletions have the same breakpoint as described by others [8, 14] , i.e. deletion of a large fragment from c.1883G in CLCNKA Exon 17 to c.230-186T in CLCNKB Intron 3. (Figure 1 ) There were no correlations between the type of CLCNKB mutations and clinical presentations of the patients (Table 3 ).
All 26 patients received potassium supplements with or without potassium-sparing diuretics (spironolactone or amiloride), but only some of them were prescribed indomethacin or other non-steroidal anti-inflammatory drugs (NSAID) and magnesium supplements (Table 4) . During the follow-up period, two patients with cBS developed chronic renal failure. One patient developed proteinuria at the age of 7 years, and a renal biopsy at the point of diagnosis revealed pathologic findings of perihilar variant of focal glomerular segmental sclerosis (FSGS). He developed end-stage renal disease at the age of 12 years. Another patient in our cohort developed persistent renal dysfunction of unknown cause at the age of 8 years. A renal biopsy was not performed on this patient, and he did not have nephrocalcinosis.
Discussion
Several studies have reported genotype-phenotype correlations in patients with BS [4, 12, [17] [18] [19] [20] [21] [22] . However, most of these reports have focused on a specific clinical variant or a specific gene, and only few comprehensive clinico-genetic studies of whole genetic and clinical variants of BS have been conducted to date [17, 18] . In this study, we conducted a nationwide multi-center study of the entire genetic basis of BS in a cohort of 23 patients.
In a large German study [17] of 85 patients with hypokalemic salt-losing tubulopathy, the genotype distribution showed 12 patients with BS I, 20 with BS II, 20 with BS III, 13 with GS and 20 with no mutation in these four genes. Another recent study [18] of 42 children with aBS or a neonatal variant of BS by a French group revealed a genotype distribution showing 19 patients with BS I, 13 with BS II, 6 with BS III and 4 with BS IV. Compared to these studies, our and a large deletion in the CLCNKB gene were detected in 54.3 and 21.7% of the 46 studied alleles, respectively, and that 21 (91.3%) of the 23 patients with BS III had at least one of these two mutations. Based on these findings, screening for these two common mutations should be the first step when testing for genetic mutation in Korean patients with BS either of the antenatal or classic variant. Interestingly, p.W610X mutation has also been reported as a common mutation in the neighboring Japan [19] , which strongly suggests that it is a founder mutation in both populations. Total or partial large deletions in the CLCNKB gene have been reported frequently, and these deletions could be the result 
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of non-homologous recombination of the CLCNKB and CLCNKA genes, which are located very close to each other and have almost identical sequences [2, 15] . Diverse manifestations of BS III, including severe aBS, typical cBS and mixed Bartter-Gitelman phenotype, have been reported in a large number of articles [11, 13, 15, 23] . Although hypomagnesemia and hypocalciuria are by definition features of GS, these findings are also present in some patients with BS [17, 24] , and this overlap of symptoms often makes it difficult to clearly separate GS from cBS by their clinical manifestations. In a recent large cohort study [25] of 448 unrelated patients suspected of having GS, CLCNKB mutations were detected in 14 (3%) patients with no SLC12A3 mutation. Nozu et al. [26] reported that even diuretic responses revealed substantial overlap between BS III and GS patients. They conducted diuretic tests using furosemide and thiazide for patients with genetically proven BS or GS. Patients with BS I showed no response to furosemide and a good response to thiazide, whereas those with the GS showed no response to thiazide and a good response to furosemide, as expected. However, patients with BS II showed a good response to both diuretics and those with BS III showed no response to thiazide and a normal response to furosemide. These results indicate that defects in ROMK are unlikely to affect NKCC2 and NCCT functions and that defects in ClC-Kb cause secondary dysfunction of NCCT but not NKCC2. The phenotypic heterogeneity of BS III probably reflects the wide distribution of ClC-Kb in the distal nephron [27] , and malfunction of ClC-Kb may disturb intracellular chloride concentration and cause secondary NCCT dysfunction [26, 28] . Furthermore, it is difficult to draw a sharp line between aBS and cBS in some cases. In fact, in our study, two patients manifested the clinical features of BS at their ages of 4 and 10 months, but they were classified as aBS because they had a history of polyhydramnios. Therefore, clinical typing of aBS, cBS and GS is confusing and somewhat impractical in some cases. Recently, Seyberth [7] suggested a new classification of BS and GS with three subtypes: distal convoluted tubule dysfunction caused by a defect in NCCT or ClC-Kb, loop dysfunction resulting from a defect in NKCC2 or ROMK and combined dysfunction following a defect in barttin or digenic defects in ClC-Ka and ClC-Kb.
Several factors have been reported to influence the renal survival of patients with BS, including recurrent episodes of dehydration during infancy, chronic hypokalemia, longterm use of NSAID, nephrocalcinosis and BSND mutations [5, [29] [30] [31] . In addition, some patients with BS or GS develop FSGS, which may lead to chronic renal failure [31] [32] [33] . In our study, two patients developed chronic renal dysfunction later in their life, which was associated with the development of perihilar type of FSGS in one of those. A possible explanation for the development of FSGS in one of the two patients is that post-adaptive chronic glomerular hyperfiltration results from chronic salt loss, thus activating the renin-angiotensin-aldosterone system [33, 34] . The cause of renal dysfunction for the other patient was unclear. Although he had taken indomethacin for 8 years before the development of renal dysfunction, we were unable to obtain renal pathologic data. The role of long-term treatment with indomethacin on renal dysfunction and histologic alterations in patients with hypokalemic salt-losing tubulopathies is not yet confirmed [35] .
In summary, BS III was found to be the most common genotype in both patients with aBS and cBS in Korea, and the p.W610X mutation and large deletion in the CLCNKB gene were the two most common mutations, comprising 76% of the prevalence in BS. The molecular diagnostic steps for patients with BS in our population should be designed with these peculiar genotype distributions taken into account. BS III typically manifests cBS phenotype but can also manifest aBS or GS phenotypes. Therefore, the current clinical classification of aBS, cBS and GS is arbitrary, confusing and does not correlate with genetic subtyping in some patients. Thus, a more clinically relevant classification is required.
